Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Sepsis Diagnostics Market

Sepsis Diagnostics Market Size, Share & Trends Analysis Report, By Product Type (Instruments, Consumables & Reagents, Software & Services), By Technology (Microbiology-Based Diagnostics, Molecular Diagnostics, Immunoassays, Biomarker-Based Testing), By End User (Hospitals & ICUs, Diagnostic Laboratories, Research & Academic Institutes), Forecast Period (2026-2035)

Published: Jun 2026 | Report Code: OMR2029806 | Category : Medical Devices | Delivery Format: /

Industry Overview

Sepsis diagnostics market was valued at $958.5 million in 2025 and is projected to reach approximately $2021.1 million by 2035, growing at a CAGR of 7.8% during the forecast period from 2026 to 2035. The market growth is primarily driven by the rising prevalence of bloodstream infections, increasing incidence of hospital-acquired infections (HAIs), and growing adoption of rapid molecular diagnostic technologies in intensive care settings.

According to the World Health Organization (WHO), sepsis affects nearly 49 million people annually worldwide and causes approximately 11 million deaths each year, accounting for nearly 20% of global deaths. Rising antimicrobial resistance (AMR) is further increasing the demand for advanced diagnostics capable of identifying pathogens rapidly and accurately. The U.S. Centers for Disease Control and Prevention (CDC) estimates that at least 1.7 million adults in the United States develop sepsis annually, creating strong demand for rapid testing systems in hospitals and emergency departments.

Healthcare institutions are increasingly adopting molecular diagnostics, automated blood culture systems, immunoassays, and biomarker-based testing solutions to improve patient outcomes and reduce mortality rates. Growth in ICU admissions, healthcare infrastructure modernization, and increasing awareness regarding early disease diagnosis are further supporting market expansion globally.

Market Dynamics

Driver: Rising Burden of Sepsis and Hospital-Acquired Infections Accelerating Demand for Rapid Diagnostics

The increasing global burden of sepsis and healthcare-associated infections is one of the major factors driving the growth of the sepsis diagnostics market. According to WHO, approximately 1 in every 5 deaths worldwide is associated with sepsis, while neonatal sepsis remains a major cause of mortality in low- and middle-income countries. The growing prevalence of antimicrobial resistance has increased the need for early pathogen detection technologies to support timely clinical intervention and antibiotic stewardship programs.

Hospitals and diagnostic laboratories are increasingly investing in multiplex PCR platforms, automated blood culture systems, and biomarker-based testing technologies to reduce diagnostic turnaround time. In 2025, bioMérieux SA expanded deployment of BIOFIRE® syndromic testing platforms across hospitals and critical care settings to strengthen infectious disease testing capabilities. Similarly, Thermo Fisher Scientific Inc. increased investments in molecular diagnostics manufacturing capacity to address the rising demand for infectious disease assays. Increasing healthcare expenditure and modernization of laboratory infrastructure across developed and emerging economies are expected to continue driving market growth over the forecast period.

Challenge: High Diagnostic Costs and Complex Laboratory Infrastructure Limiting Adoption

Despite strong market growth potential, high costs associated with advanced molecular diagnostics and automated microbiology systems remain significant challenges for market expansion. PCR platforms, syndromic testing panels, and biomarker-based assays require sophisticated laboratory infrastructure, trained personnel, and continuous reagent supply, which can limit adoption in resource-constrained healthcare facilities.

Conventional blood culture systems remain widely used due to lower costs, despite longer turnaround times compared to molecular diagnostics. In many developing countries, limited reimbursement policies and inadequate healthcare infrastructure continue to restrict the adoption of advanced sepsis diagnostics technologies. Supply chain disruptions affecting reagent availability and semiconductor shortages impacting diagnostic instrument manufacturing have also created operational challenges for manufacturers.

To address these limitations, companies are focusing on automation, decentralized testing, and cost-effective point-of-care solutions. Danaher Corporation, through Cepheid, has expanded rapid molecular testing platforms designed for simplified hospital workflows, while Roche Diagnostics continues to strengthen biomarker-based testing solutions to improve cost-efficiency and accessibility in critical care diagnostics.

Market Segmentation

  • Based on the Product Type, the market is segmented into Instruments, Consumables & Reagents, and Software & Services.
  • Based on the Technology, the market is segmented into Microbiology-Based Diagnostics, Molecular Diagnostics, Immunoassays, and Biomarker-Based Testing.
  • Based on the End User, the market is segmented into Hospitals & ICUs, Diagnostic Laboratories, and Research & Academic Institutes.

Consumables & Reagents Segment Leads the Market

The consumables & reagents segment accounted for the largest share of the global sepsis diagnostics market, owing to recurring demand for blood culture bottles, assay kits, reagents, biomarker cartridges, and molecular testing panels used in continuous diagnostic workflows. Hospitals and diagnostic laboratories require regular replenishment of consumables, creating a stable recurring revenue stream for manufacturers.

Companies such as bioMérieux SA, Roche Diagnostics, and BD have expanded their consumables portfolios between 2022 and 2026 to support growing demand for rapid infectious disease testing. Increasing utilization of multiplex PCR panels and biomarker assays in ICUs is further driving segment growth. The rise in bloodstream infections and growing focus on early sepsis detection are expected to sustain strong demand for consumables and reagents globally.

Molecular Diagnostics Segment to Record Strong Growth

The molecular diagnostics segment is expected to witness the fastest growth during the forecast period due to increasing adoption of rapid pathogen identification technologies in hospitals and critical care facilities. Molecular testing enables faster and more accurate detection of bacteria, fungi, and viral pathogens compared to conventional blood culture systems.

Growing integration of syndromic testing panels, multiplex PCR systems, and nucleic acid amplification technologies is supporting market expansion. In 2024 and 2025, companies including Cepheid, QIAGEN, and Thermo Fisher Scientific introduced advanced molecular workflows focused on infectious disease diagnostics and sepsis management. Rising investments in laboratory automation and precision diagnostics are further accelerating the adoption of molecular diagnostic solutions worldwide.

Regional Outlook

The global sepsis diagnostics market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States accounted for the largest share of the global sepsis diagnostics market due to advanced healthcare infrastructure, high ICU admission rates, and strong adoption of molecular diagnostics technologies. According to the CDC, approximately 1.7 million adults develop sepsis annually in the U.S., with nearly 350,000 deaths associated with sepsis each year. Rising healthcare investments and the strong presence of leading diagnostics manufacturers, including Roche, Thermo Fisher Scientific, and BD, are supporting market growth. Increasing implementation of antimicrobial stewardship programs and rapid testing protocols across hospitals is further driving demand for advanced sepsis diagnostics solutions in the country.

China to Record Strong Growth

China is projected to witness significant growth during the forecast period due to expanding healthcare infrastructure, rising infectious disease burden, and increasing investments in clinical laboratory modernization. The country is rapidly adopting molecular diagnostics technologies to improve infectious disease management and hospital testing efficiency. Government initiatives focused on strengthening healthcare systems and increasing access to advanced diagnostics are contributing to market expansion. Growing hospital construction activities, increasing ICU capacity, and rising healthcare expenditure are expected to accelerate demand for automated microbiology systems, biomarker testing, and molecular diagnostics platforms across China.

Competitive Landscape

The global sepsis diagnostics market is moderately consolidated, with major players focusing on technological innovation, product expansion, and strategic collaborations to strengthen their market position. Companies are investing heavily in molecular diagnostics, automated blood culture systems, and biomarker-based testing solutions to improve diagnostic speed and accuracy. F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., bioMérieux SA, Danaher Corporation (Cepheid, Beckman Coulter), and Becton, Dickinson and Company (BD) are among the leading companies operating in the market. These companies are emphasizing syndromic testing platforms, multiplex PCR technologies, and AI-driven laboratory automation solutions to enhance their competitive positioning globally.

Recent Developments

  • In June 2026, Thermo Fisher Scientific showcased its infectious disease and microbiology diagnostic solutions at ASM Microbe 2026, including advanced culture media technologies for pathogen detection and antimicrobial resistance monitoring, supporting improved diagnostic workflows relevant to bloodstream infections and sepsis management.
  • In January 2025, bioMérieux announced the acquisition of SpinChip Diagnostics ASA to strengthen its point-of-care diagnostics portfolio. The acquisition expands bioMérieux’s capabilities in rapid near-patient testing through SpinChip’s immunoassay platform, supporting faster acute care diagnostics and enhancing the company’s broader infectious disease and critical care diagnostics strategy.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global sepsis diagnostics market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Sepsis Diagnostics Market Sales Analysis – Product Type | Technology | End User ($ Million)
  • Sepsis Diagnostics Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Sepsis Diagnostics Market Trends

2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Sepsis Diagnostics Market

2.3.1 Competitive Rivalry

2.3.2 Threat of New Entrants

2.3.3 Bargaining Power of Suppliers

2.3.4 Bargaining Power of Buyers

2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Sepsis Diagnostics Market: Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Sepsis Diagnostics Market: Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Sepsis Diagnostics Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Sepsis Diagnostics Market Revenue and Share by Manufacturers

  • Sepsis Diagnostics Product Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 F. Hoffmann-La Roche Ltd

4.2.1.1 Overview

4.2.1.2 Product Portfolio

4.2.1.3 Financial Analysis

4.2.1.4 SWOT Analysis

4.2.1.5 Business Strategy

4.2.2 Thermo Fisher Scientific Inc.

4.2.2.1 Overview

4.2.2.2 Product Portfolio

4.2.2.3 Financial Analysis

4.2.2.4 SWOT Analysis

4.2.2.5 Business Strategy

4.2.3 bioMérieux SA

4.2.3.1 Overview

4.2.3.2 Product Portfolio

4.2.3.3 Financial Analysis

4.2.3.4 SWOT Analysis

4.2.3.5 Business Strategy

4.2.4 Danaher Corporation (Cepheid, Beckman Coulter)

4.2.4.1 Overview

4.2.4.2 Product Portfolio

4.2.4.3 Financial Analysis

4.2.4.4 SWOT Analysis

4.2.4.5 Business Strategy

4.2.5 Becton, Dickinson and Company (BD)

4.2.5.1 Overview

4.2.5.2 Product Portfolio

4.2.5.3 Financial Analysis

4.2.5.4 SWOT Analysis

4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition

4.3.2 Product Launch

4.3.3 Partnership And Collaboration

  1. Global Sepsis Diagnostics Market Sales Analysis by Product Type ($ Million)

5.1 Instruments

5.2 Consumables & Reagents

5.3 Software & Services

  1. Global Sepsis Diagnostics Market Sales Analysis by Technology ($ Million)

6.1 Microbiology-Based Diagnostics

6.2 Molecular Diagnostics

6.3 Immunoassays

6.4 Biomarker-Based Testing

  1. Global Sepsis Diagnostics Market Sales Analysis by End User ($ Million)

7.1 Hospitals & ICUs

7.2 Diagnostic Laboratories

7.3 Research & Academic Institutes

  1. Regional Analysis

8.1 North American Sepsis Diagnostics Market Sales Analysis – Product Type | Technology | End User | Country ($ Million)

8.1.1 United States

8.1.2 Canada

8.2 European Sepsis Diagnostics Market Sales Analysis – Product Type | Technology | End User | Country ($ Million)

8.2.1 UK

8.2.2 Germany

8.2.3 Italy

8.2.4 Spain

8.2.5 France

8.2.6 Russia

8.2.7 Rest of Europe

8.3 Asia-Pacific Sepsis Diagnostics Market Sales Analysis – Product Type | Technology | End User | Country ($ Million)

8.3.1 China

8.3.2 Japan

8.3.3 South Korea

8.3.4 India

8.3.5 Australia & New Zealand

8.3.6 ASEAN Countries

8.3.7 Rest of Asia-Pacific

8.4 Rest of the World Sepsis Diagnostics Market Sales Analysis – Product Type | Technology | End User | Country ($ Million)

8.4.1 Latin America

8.4.2 Middle East and Africa

  1. Company Profiles

9.1 Abbott Laboratories

9.1.1 Quick Facts

9.1.2 Company Overview

9.1.3 Product Portfolio

9.1.4 Business Strategies

9.2 Accelerate Diagnostics Inc.

9.2.1 Quick Facts

9.2.2 Company Overview

9.2.3 Product Portfolio

9.2.4 Business Strategies

9.3 bioMérieux (BioFire Diagnostics)

9.3.1 Quick Facts

9.3.2 Company Overview

9.3.3 Product Portfolio

9.3.4 Business Strategies

9.4 Bio-Rad Laboratories Inc.

9.4.1 Quick Facts

9.4.2 Company Overview

9.4.3 Product Portfolio

9.4.4 Business Strategies

9.5 Bruker Corporation

9.5.1 Quick Facts

9.5.2 Company Overview

9.5.3 Product Portfolio

9.5.4 Business Strategies

9.6 Curetis GmbH (OpGen)

9.6.1 Quick Facts

9.6.2 Company Overview

9.6.3 Product Portfolio

9.6.4 Business Strategies

9.7 DiaSorin S.p.A.

9.7.1 Quick Facts

9.7.2 Company Overview

9.7.3 Product Portfolio

9.7.4 Business Strategies

9.8 EKF Diagnostics Holdings plc

9.8.1 Quick Facts

9.8.2 Company Overview

9.8.3 Product Portfolio

9.8.4 Business Strategies

9.9 GenMark Diagnostics (Roche)

9.9.1 Quick Facts

9.9.2 Company Overview

9.9.3 Product Portfolio

9.9.4 Business Strategies

9.10 Hologic Inc.

9.10.1 Quick Facts

9.10.2 Company Overview

9.10.3 Product Portfolio

9.10.4 Business Strategies

9.11 Immunexpress Inc.

9.11.1 Quick Facts

9.11.2 Company Overview

9.11.3 Product Portfolio

9.11.4 Business Strategies

9.12 Molzym GmbH & Co. KG

9.12.1 Quick Facts

9.12.2 Company Overview

9.12.3 Product Portfolio

9.12.4 Business Strategies

9.13 Nova Biomedical

9.13.1 Quick Facts

9.13.2 Company Overview

9.13.3 Product Portfolio

9.13.4 Business Strategies

9.14 QIAGEN N.V.

9.14.1 Quick Facts

9.14.2 Company Overview

9.14.3 Product Portfolio

9.14.4 Business Strategies

9.15 Randox Laboratories Ltd.

9.15.1 Quick Facts

9.15.2 Company Overview

9.15.3 Product Portfolio

9.15.4 Business Strategies

9.16 Response Biomedical Corp.

9.16.1 Quick Facts

9.16.2 Company Overview

9.16.3 Product Portfolio

9.16.4 Business Strategies

9.17 Seegene Inc.

9.17.1 Quick Facts

9.17.2 Company Overview

9.17.3 Product Portfolio

9.17.4 Business Strategies

9.18 Siemens Healthineers AG

9.18.1 Quick Facts

9.18.2 Company Overview

9.18.3 Product Portfolio

9.18.4 Business Strategies

9.19 T2 Biosystems Inc.

9.19.1 Quick Facts

9.19.2 Company Overview

9.19.3 Product Portfolio

9.19.4 Business Strategies

9.20 Trinity Biotech plc

9.20.1 Quick Facts

9.20.2 Company Overview

9.20.3 Product Portfolio

9.20.4 Business Strategies

1. Global Sepsis Diagnostics Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

2. Global Instruments Sepsis Diagnostics Market Research and Analysis by Region, 2025–2035 ($ Million) 

3. Global Consumables & Reagents Sepsis Diagnostics Market Research and Analysis by Region, 2025–2035 ($ Million) 

4. Global Software & Services Sepsis Diagnostics Market Research and Analysis by Region, 2025–2035 ($ Million) 

5. Global Sepsis Diagnostics Market Research and Analysis by Technology, 2025–2035 ($ Million) 

6. Global Microbiology-Based Diagnostics Sepsis Diagnostics Market Research and Analysis by Region, 2025–2035 ($ Million) 

7. Global Molecular Diagnostics Sepsis Diagnostics Market Research and Analysis by Region, 2025–2035 ($ Million) 

8. Global Immunoassays Sepsis Diagnostics Market Research and Analysis by Region, 2025–2035 ($ Million) 

9. Global Biomarker-Based Testing Sepsis Diagnostics Market Research and Analysis by Region, 2025–2035 ($ Million) 

10. Global Sepsis Diagnostics Market Research and Analysis by End User, 2025–2035 ($ Million) 

11. Global Sepsis Diagnostics for Hospitals & ICUs Market Research and Analysis by Region, 2025–2035 ($ Million) 

12. Global Sepsis Diagnostics for Diagnostic Laboratories Market Research and Analysis by Region, 2025–2035 ($ Million) 

13. Global Sepsis Diagnostics for Research & Academic Institutes Market Research and Analysis by Region, 2025–2035 ($ Million) 

14. Global Sepsis Diagnostics Market Research and Analysis by Region, 2025–2035 ($ Million) 

15. North America Sepsis Diagnostics Market Research and Analysis by Country, 2025–2035 ($ Million) 

16. North America Sepsis Diagnostics Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

17. North America Sepsis Diagnostics Market Research and Analysis by Technology, 2025–2035 ($ Million) 

18. North America Sepsis Diagnostics Market Research and Analysis by End User, 2025–2035 ($ Million) 

19. Europe Sepsis Diagnostics Market Research and Analysis by Country, 2025–2035 ($ Million) 

20. Europe Sepsis Diagnostics Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

21. Europe Sepsis Diagnostics Market Research and Analysis by Technology, 2025–2035 ($ Million) 

22. Europe Sepsis Diagnostics Market Research and Analysis by End User, 2025–2035 ($ Million) 

23. Asia-Pacific Sepsis Diagnostics Market Research and Analysis by Country, 2025–2035 ($ Million) 

24. Asia-Pacific Sepsis Diagnostics Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

25. Asia-Pacific Sepsis Diagnostics Market Research and Analysis by Technology, 2025–2035 ($ Million) 

26. Asia-Pacific Sepsis Diagnostics Market Research and Analysis by End User, 2025–2035 ($ Million) 

27. Rest of the World Sepsis Diagnostics Market Research and Analysis by Region, 2025–2035 ($ Million) 

28. Rest of the World Sepsis Diagnostics Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

29. Rest of the World Sepsis Diagnostics Market Research and Analysis by Technology, 2025–2035 ($ Million) 

30. Rest of the World Sepsis Diagnostics Market Research and Analysis by End User, 2025–2035 ($ Million) 

31. Global Sepsis Diagnostics Market – Top 5 Companies Market Share Analysis, 2025 (%) 

32. Global Sepsis Diagnostics Market – Top 5 Companies Revenue Comparison, 2025–2035 ($ Million) 

1. Global Sepsis Diagnostics Market Share by Product Type, 2025 Vs 2035 (%) 

2. Global Instruments Sepsis Diagnostics Market Research and Analysis by Region, 2025 Vs 2035 (%) 

3. Global Consumables & Reagents Sepsis Diagnostics Market Research and Analysis by Region, 2025 Vs 2035 (%) 

4. Global Software & Services Sepsis Diagnostics Market Research and Analysis by Region, 2025 Vs 2035 (%) 

5. Global Sepsis Diagnostics Market Share by Technology, 2025 Vs 2035 (%) 

6. Global Microbiology-Based Diagnostics Sepsis Diagnostics Market Research and Analysis by Region, 2025 Vs 2035 (%) 

7. Global Molecular Diagnostics Sepsis Diagnostics Market Research and Analysis by Region, 2025 Vs 2035 (%) 

8. Global Immunoassays Sepsis Diagnostics Market Research and Analysis by Region, 2025 Vs 2035 (%) 

9. Global Biomarker-Based Testing Sepsis Diagnostics Market Research and Analysis by Region, 2025 Vs 2035 (%) 

10. Global Sepsis Diagnostics Market Share by End User, 2025 Vs 2035 (%) 

11. Global Sepsis Diagnostics for Hospitals & ICUs Market Research and Analysis by Region, 2025 Vs 2035 (%) 

12. Global Sepsis Diagnostics for Diagnostic Laboratories Market Research and Analysis by Region, 2025 Vs 2035 (%) 

13. Global Sepsis Diagnostics for Research & Academic Institutes Market Research and Analysis by Region, 2025 Vs 2035 (%) 

14. Global Sepsis Diagnostics Market Share by Region, 2025 Vs 2035 (%) 

15. U.S. Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

16. Canada Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

17. UK Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

18. France Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

19. Germany Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

20. Italy Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

21. Spain Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

22. Russia Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

23. India Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

24. China Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

25. Japan Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

26. South Korea Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

27. Australia & New Zealand Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

28. ASEAN Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

29. Rest of Asia-Pacific Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

30. Latin America Sepsis Diagnostics Market Size, 2025–2035 ($ Million) 

31. Middle East & Africa Sepsis Diagnostics Market Size, 2025–2035 ($ Million)

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The global sepsis diagnostics market was valued at $958.5 million in 2025 and is projected to reach $2021.1 million by 2035.
The sepsis diagnostics market is expected to grow at a CAGR of 7.8% during the forecast period from 2026 to 2035.
The consumables & reagents segment dominates the sepsis diagnostics market due to recurring demand for assay kits, blood culture bottles, and molecular testing reagents.
North America leads the sepsis diagnostics market owing to advanced healthcare infrastructure, high sepsis incidence, and rapid adoption of molecular diagnostics technologies.
The molecular diagnostics segment is expected to witness the fastest growth due to increasing adoption of multiplex PCR platforms and rapid pathogen identification technologies.